Alamar Biosciences announced that its NULISA platform was prominently featured in over 140 scientific presentations at the 2026 Alzheimer's Association International Conference (AAIC) in London, highlighting its growing adoption in Alzheimer's research. The company showcased new data on eMTBR-Tau and BD-pTau217 biomarkers, which improve early detection and disease staging by analyzing multiple proteins simultaneously. This advancement could lead to more precise and earlier Alzheimer's diagnosis, with further insights expected from Alamar's upcoming AAIC workshop. The platform's sensitivity surpasses current market technologies, positioning Alamar as a leader in precision proteomics for neurodegenerative diseases.
Alamar Biosciences presented extensive data from its NULISA platform at the AAIC 2026 conference, highlighting advances in blood-based biomarkers for Alzheimer's detection and staging. The company emphasized new findings on eMTBR-Tau and BD-pTau217, ...
Holtec Nuclear Corporation has filed a registration statement with the U.S. SEC for a proposed initial public offering (IPO) of its Class A common stock, planning to list on Nasdaq under the symbol "HNUC." The offering details, including share count ...
Meta has halted a new AI feature on Instagram that generated images using public account photos without user consent, following widespread privacy and copyright concerns. The feature was automatically enabled for public profiles, sparking criticism f...
Bitcoin governance controversy has resurfaced as David Bailey accused developer Luke Dashjr of introducing a blacklist in 2014 Gentoo Bitcoin software, blocking gambling transactions. Dashjr now advocates BIP-110, aiming to restrict non-financial dat...
Halper Sadeh LLC is investigating whether shareholders of Simulations Plus (SLP), Huntsman Corporation (HUN), Olin Corporation (OLN), and Pulmatrix (PULM) are receiving fair deals in recent mergers and sales. The firm suspects insiders may gain finan...
